Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,350

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis

Open access
Cevik, Muge, Tate, Matthew, Lloyd, Ollie, Maraolo, Alberto Enrico, Schafers, Jenna, Ho, Antonia·2021·The Lancet Microbe
DOI 10.1016/s2666-5247(20)30172-5

Published version of a preprint

Open this paper in CoChat — free account

Abstract

BACKGROUND: Viral load kinetics and duration of viral shedding are important determinants for disease transmission. We aimed to characterise viral load dynamics, duration of viral RNA shedding, and viable virus shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in various body fluids, and to compare SARS-CoV-2, SARS-CoV, and Middle East respiratory syndrome coronavirus (MERS-CoV) viral dynamics. METHODS: , and the grey literature, for research articles published between Jan 1, 2003, and June 6, 2020. We included case series (with five or more participants), cohort studies, and randomised controlled trials that reported SARS-CoV-2, SARS-CoV, or MERS-CoV infection, and reported viral load kinetics, duration of viral shedding, or viable virus. Two authors independently extracted data from published studies, or contacted authors to request data, and assessed study quality and risk of bias using the Joanna Briggs Institute Critical Appraisal Checklist tools. We calculated the mean duration of viral shedding and 95% CIs for every study included and applied the random-effects model to estimate a pooled effect size. We used a weighted meta-regression with an unrestricted maximum likelihood model to assess the effect of potential moderators on the pooled effect size. This study is registered with PROSPERO, CRD42020181914. FINDINGS: 79 studies (5340 individuals) on SARS-CoV-2, eight studies (1858 individuals) on SARS-CoV, and 11 studies (799 individuals) on MERS-CoV were included. Mean duration of SARS-CoV-2 RNA shedding was 17·0 days (95% CI 15·5-18·6; 43 studies, 3229 individuals) in upper respiratory tract, 14·6 days (9·3-20·0; seven studies, 260 individuals) in lower respiratory tract, 17·2 days (14·4-20·1; 13 studies, 586 individuals) in stool, and 16·6 days (3·6-29·7; two studies, 108 individuals) in serum samples. Maximum shedding duration was 83 days in the upper respiratory tract, 59 days in the lower respiratory tract, 126 days in stools, and 60 days in serum. Pooled mean SARS-CoV-2 shedding duration was positively associated with age (slope 0·304 [95% CI 0·115-0·493]; p=0·0016). No study detected live virus beyond day 9 of illness, despite persistently high viral loads, which were inferred from cycle threshold values. SARS-CoV-2 viral load in the upper respiratory tract appeared to peak in the first week of illness, whereas that of SARS-CoV peaked at days 10-14 and that of MERS-CoV peaked at days 7-10. INTERPRETATION: Although SARS-CoV-2 RNA shedding in respiratory and stool samples can be prolonged, duration of viable virus is relatively short-lived. SARS-CoV-2 titres in the upper respiratory tract peak in the first week of illness. Early case finding and isolation, and public education on the spectrum of illness and period of infectiousness are key to the effective containment of SARS-CoV-2. FUNDING: None.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2666-5247(20)30172-5

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 101

  1. Cevik, 2020, COVID-19 pandemic—a focused review for clinicians, Clin Microbiol Infect, 26, 842, 10.1016/j.cmi.2020.04.023 · DOI · Paper page
  2. Zou, 2020, SARS-CoV-2 viral load in upper respiratory specimens of infected patients, N Engl J Med, 382, 1177, 10.1056/NEJMc2001737 · DOI · Paper page
  3. Kim, 2020, Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19, J Korean Med Sci, 35, e142, 10.3346/jkms.2020.35.e142 · DOI · Paper page
  4. Cai, 2020, A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features, Clin Infect Dis, 71, 1547, 10.1093/cid/ciaa198 · DOI · Paper page
  5. Han, 2020, Viral RNA load in mildly symptomatic and asymptomatic children with COVID-19, Seoul, South Korea, Emerg Infect Dis, 26, 2497, 10.3201/eid2610.202449 · DOI · Paper page
  6. L'Huillier, 2020, Culture-competent SARS-CoV-2 in nasopharynx of symptomatic neonates, children, and adolescents, Emerg Infect Dis, 26, 2494, 10.3201/eid2610.202403 · DOI
  7. Tan, 2020, Epidemiologic and clinical characteristics of 10 children with coronavirus disease 2019 in Changsha, China, J Clin Virol, 127, 10.1016/j.jcv.2020.104353 · DOI
  8. Wu, 2020, Epidemiological and clinical characteristics of children with coronavirus disease 2019, medRxiv
  9. Xu, 2020, Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding, Nat Med, 26, 502, 10.1038/s41591-020-0817-4 · DOI · Paper page
  10. Zhang, 2020, Early viral clearance and antibody kinetics of COVID-19 among asymptomatic carriers, medRxiv
  11. Lavezzo, 2020, Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo', Nature, 584, 425, 10.1038/s41586-020-2488-1 · DOI · Paper page
  12. He, 2020, Temporal dynamics in viral shedding and transmissibility of COVID-19, Nat Med, 26, 672, 10.1038/s41591-020-0869-5 · DOI · Paper page
  13. Kujawski, 2020, Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States, Nat Med, 26, 861, 10.1038/s41591-020-0877-5 · DOI · Paper page
  14. Tan, 2020, Viral kinetics and antibody responses in patients with COVID-19, medRxiv
  15. To, 2020, Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study, Lancet Infect Dis, 20, 565, 10.1016/S1473-3099(20)30196-1 · DOI · Paper page
  16. Wyllie, 2020, Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2, N Engl J Med, 383, 1283, 10.1056/NEJMc2016359 · DOI · Paper page
  17. Young, 2020, Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore, JAMA, 323, 1488, 10.1001/jama.2020.3204 · DOI · Paper page
  18. Huang, 2020, Long period dynamics of viral load and antibodies for SARS-CoV-2 infection: an observational cohort study, medRxiv
  19. Zhang, 2020, Virus shedding patterns in nasopharyngeal and fecal specimens of COVID-19 patients, medRxiv
  20. Zheng, 2020, Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study, BMJ, 369
  21. Cai, 2020, COVID-19 in a designated infectious diseases hospital outside Hubei Province, China, Allergy, 75, 1742, 10.1111/all.14309 · DOI · Paper page
  22. Chen, 2020, Clinical progression of patients with COVID-19 in Shanghai, China, J Infect, 80, e1, 10.1016/j.jinf.2020.03.004 · DOI · Paper page
  23. Chen, 2020, Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19, Int J Infect Dis, 98, 252, 10.1016/j.ijid.2020.06.091 · DOI
  24. Chen, 2020, The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients, J Med Virol, 92, 833, 10.1002/jmv.25825 · DOI · Paper page
  25. Fan, 2020, Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: a single-center, retrospective, observational study, medRxiv
  26. Fang, 2020, Comparisons of viral shedding time of SARS-CoV-2 of different samples in ICU and non-ICU patients, J Infect, 81, 147
  27. Shi, 2020, Systemic inflammatory cytokines associate with SARS-CoV-2 viral shedding time in Covid-19 inpatients, Res Sq
  28. Tan, 2020, Validation of predictors of disease severity and outcomes in COVID-19 patients: a descriptive and retrospective study, Med, 10.1016/j.medj.2020.05.002 · DOI
  29. Yongchen, 2020, Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients, Emerg Microbes Infect, 9, 833, 10.1080/22221751.2020.1756699 · DOI · Paper page
  30. Hu, 2020, Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19, Sci Total Environ, 728, 10.1016/j.scitotenv.2020.138812 · DOI
  31. Xu, 2020, Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19), Clin Infect Dis, 71, 799, 10.1093/cid/ciaa351 · DOI · Paper page
  32. Yan, 2020, Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection, Eur Respir J, 56, 10.1183/13993003.00799-2020 · DOI
  33. Wu, 2020, Prolonged presence of SARS-CoV-2 viral RNA in faecal samples, Lancet Gastroenterol Hepatol, 5, 434, 10.1016/S2468-1253(20)30083-2 · DOI · Paper page
  34. Tian, 2020, Clinical research and factors associated with prolonged duration of viral shedding in patients with COVID-19, Res Sq
  35. Zhou, 2020, The duration of viral shedding of discharged patients with severe COVID-19, Clin Infect Dis, 10.1093/cid/ciaa451 · DOI
  36. Sakurai, 2020, Natural history of asymptomatic SARS-CoV-2 infection, N Engl J Med, 383, 885, 10.1056/NEJMc2013020 · DOI · Paper page
  37. Talmy, 2020, Duration of SARS-CoV-2 detection in Israel Defense Forces soldiers with mild COVID-19, J Med Virol
  38. Xiao, 2020, Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients, Clin Infect Dis, 10.1093/cid/ciaa460 · DOI · Paper page
  39. Shastri, 2020, Delayed clearance of SARS-CoV2 in male compared to female patients: high ACE2 expression in testes suggests possible existence of gender-specific viral reservoirs, medRxiv
  40. Ling, 2020, Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients, Chin Med J, 133, 1039, 10.1097/CM9.0000000000000774 · DOI · Paper page
  41. Zha, 2020, Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19), Med J Aust, 212, 416, 10.5694/mja2.50577 · DOI · Paper page
  42. Liang, 2020, Corticosteroid treatment in critically ill patients with COVID-19: a retrospective cohort study, Res Sq
  43. Hung, 2020, Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial, Lancet, 395, 1695, 10.1016/S0140-6736(20)31042-4 · DOI · Paper page
  44. Huang, 2020, Chloroquine, arbidol (umifenovir) or lopinavir/ritonavir as the antiviral monotherapy for COVID-19 patients: a retrospective cohort study, Res Sq
  45. Zhou, 2020, Viral dynamics in asymptomatic patients with COVID-19, Int J Infect Dis, 96, 288, 10.1016/j.ijid.2020.05.030 · DOI · Paper page
  46. Chau, 2020, The natural history and transmission potential of asymptomatic SARS-CoV-2 infection, Clin Infect Dis
  47. Arons, 2020, Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility, N Engl J Med, 382, 2081, 10.1056/NEJMoa2008457 · DOI · Paper page
  48. Hu, 2020, Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China, Sci China Life Sci, 63, 706, 10.1007/s11427-020-1661-4 · DOI · Paper page
  49. Yang, 2020, Comparison of clinical characteristics of patients with asymptomatic vs symptomatic coronavirus disease 2019 in Wuhan, China, JAMA Netw Open, 3, 10.1001/jamanetworkopen.2020.10182 · DOI · Paper page
  50. Bullard, 2020, Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples, Clin Infect Dis, 10.1093/cid/ciaa638 · DOI · Paper page
  51. La Scola, 2020, Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards, Eur J Clin Microbiol Infect Dis, 39, 1059, 10.1007/s10096-020-03913-9 · DOI · Paper page
  52. Le, 2020, Severe acute respiratory syndrome coronavirus 2 shedding by travelers, Vietnam, 2020, Emerg Infect Dis, 26, 1624, 10.3201/eid2607.200591 · DOI
  53. To, 2020, Consistent detection of 2019 novel coronavirus in saliva, Clin Infect Dis, 71, 841, 10.1093/cid/ciaa149 · DOI · Paper page
  54. Xiao, 2020, Infectious SARS-CoV-2 in feces of patient with severe COVID-19, Emerg Infect Dis J, 26, 1920, 10.3201/eid2608.200681 · DOI · Paper page
  55. Andersson, 2020, SARS-CoV-2 RNA detected in blood samples from patients with COVID-19 is not associated with infectious virus, medRxiv
  56. Chang, 2020, Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection, Am J Respir Crit Care Med, 201, 1150, 10.1164/rccm.202003-0524LE · DOI · Paper page
  57. Chen, 2020, Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients, medRxiv
  58. Corman, 2020, SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission, Transfusion, 60, 1119, 10.1111/trf.15841 · DOI
  59. Fu, 2020, Virologic and clinical characteristics for prognosis of severe COVID-19: a retrospective observational study in Wuhan, China, medRxiv
  60. Huang, 2020, Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on inflammatory responses and viral clearance in COVID-19 patients: a multicenter retrospective cohort study, Res Sq
  61. Li, 2020, Prolonged SARS-CoV-2 RNA shedding: not a rare phenomenon, J Med Virol, 92, 2286, 10.1002/jmv.25952 · DOI · Paper page
  62. Lo, 2020, Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau, Int J Biol Sci, 16, 1698, 10.7150/ijbs.45357 · DOI · Paper page
  63. Lou, 2020, Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset, Eur Respir J, 56, 10.1183/13993003.00763-2020 · DOI · Paper page
  64. Pongpirul, 2020, Clinical characteristics of patients hospitalized with coronavirus disease, Thailand, Emerg Infect Dis, 26, 1580, 10.3201/eid2607.200598 · DOI
  65. Qian, 2020, Duration of SARS-CoV-2 viral shedding during COVID-19 infection, Infect Dis, 52, 511, 10.1080/23744235.2020.1748705 · DOI
  66. Quan, 2020, No SARS-CoV-2 in expressed prostatic secretion of patients with coronavirus disease 2019: a descriptive multicentre study in China, medRxiv
  67. Seah, 2020, Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients, Ophthalmology, 127, 977, 10.1016/j.ophtha.2020.03.026 · DOI · Paper page
  68. Song, 2020, Detection of 2019 novel coronavirus in semen and testicular biopsy specimen of COVID-19 patients, medRxiv
  69. Song, 2020, Clinical and epidemiological features of COVID-19 family clusters in Beijing, China, J Infect, 81, e26, 10.1016/j.jinf.2020.04.018 · DOI
  70. Tu, 2020, Analysis of factors affected the SARS-CoV-2 viral shedding time of COVID-19 patients in Anhui, China: a retrospective study, Res Sq
  71. Wang, 2020, The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China, Eur Respir J, 55, 10.1183/13993003.00398-2020 · DOI
  72. Wang, 2020, Clinical characteristics and fecal-oral transmission potential of patients with COVID-19, medRxiv
  73. Wu, 2020, Epidemiological and clinical features of imported and local patients with coronavirus disease 2019 (COVID-19) in Hainan, China, SSRN
  74. Xu, 2020, Conjunctival polymerase chain reaction-tests of 2019 novel coronavirus in patients in Shenyang, China, medRxiv
  75. Zhu, 2020, Coronavirus disease 2019 pneumonia in immunosuppressed renal transplant recipients: a summary of 10 confirmed cases in Wuhan, China, Eur Urol, 18, 18
  76. Chan, 2004, Laboratory diagnosis of SARS, Emerg Infect Dis, 10, 825, 10.3201/eid1005.030682 · DOI · Paper page
  77. Chen, 2006, Nasopharyngeal shedding of severe acute respiratory syndrome-associated coronavirus is associated with genetic polymorphisms, Clin Infect Dis, 42, 1561, 10.1086/503843 · doi:10.1086/503843
  78. Liu, 2004, Long-term SARS coronavirus excretion from patient cohort, China, Emerg Infect Dis, 10, 1841, 10.3201/eid1010.040297 · doi:10.3201/eid1010.040297
  79. Xu, 2005, Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase, Eur J Clin Microbiol Infect Dis, 24, 165, 10.1007/s10096-005-1299-5 · DOI
  80. Cheng, 2004, Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome, Lancet, 363, 1699, 10.1016/S0140-6736(04)16255-7 · DOI · Paper page
  81. Kwan, 2004, Severe acute respiratory syndrome in dialysis patients, J Am Soc Nephrol, 15, 1883, 10.1097/01.ASN.0000131522.16404.1F · doi:10.1097/01.asn.0000131522.16404.1f
  82. Leong, 2004, Virus-specific RNA and antibody from convalescent-phase SARS patients discharged from hospital, Emerg Infect Dis, 10, 1745, 10.3201/eid1010.040026 · doi:10.3201/eid1010.040026
  83. Peiris, 2003, Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study, Lancet, 361, 1767, 10.1016/S0140-6736(03)13412-5 · DOI · Paper page
  84. Min, 2016, Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity, Sci Rep, 6, 10.1038/srep25359 · DOI · Paper page
  85. Shalhoub, 2015, IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study, J Antimicrob Chemother, 70, 2129, 10.1093/jac/dkv085 · DOI
  86. Al Hosani, 2016, Response to emergence of Middle East respiratory syndrome coronavirus, Abu Dhabi, United Arab Emirates, 2013–2014, Emerg Infect Dis, 22, 1162, 10.3201/eid2207.160040 · doi:10.3201/eid2207.160040
  87. Oh, 2016, Viral load kinetics of MERS coronavirus infection, N Engl J Med, 375, 1303, 10.1056/NEJMc1511695 · DOI · Paper page
  88. Arabi, 2017, Critically ill patients with the Middle East respiratory syndrome: a multicenter retrospective cohort study, Crit Care Med, 45, 1683, 10.1097/CCM.0000000000002621 · DOI
  89. Hong, 2018, Predictors of mortality in Middle East respiratory syndrome (MERS), Thorax, 73, 286, 10.1136/thoraxjnl-2016-209313 · DOI · Paper page
  90. Corman, 2016, Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection, Clin Infect Dis, 62, 477, 10.1093/cid/civ951 · DOI · Paper page
  91. Muth, 2015, Infectious Middle East respiratory syndrome coronavirus excretion and serotype variability based on live virus isolates from patients in Saudi Arabia, J Clin Microbiol, 53, 2951, 10.1128/JCM.01368-15 · DOI
  92. Al-Jasser, 2019, Epidemiology and predictors of survival of MERS-CoV infections in Riyadh region, 2014–2015, J Infect Public Health, 12, 171, 10.1016/j.jiph.2018.09.008 · doi:10.1016/j.jiph.2018.09.008
  93. Alkendi, 2019, Descriptive epidemiology, clinical characteristics and outcomes for Middle East respiratory syndrome coronavirus (MERS-CoV) infected patients in AlAin – Abu Dhabi Emirate, J Infect Public Health, 12, 137, 10.1016/j.jiph.2018.10.099 · DOI
  94. Park, 2018, Replicative virus shedding in the respiratory tract of patients with Middle East respiratory syndrome coronavirus infection, Int J Infect Dis, 72, 8, 10.1016/j.ijid.2018.05.003 · doi:10.1016/j.ijid.2018.05.003
  95. Wang, 2020, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, 395, 1569, 10.1016/S0140-6736(20)31022-9 · DOI · Paper page
  96. Wang, 2020, Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China, BMJ Glob Health, 5, 10.1136/bmjgh-2020-002794 · DOI · Paper page
  97. Cheng, 2020, Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset, JAMA Intern Med, 180, 1156, 10.1001/jamainternmed.2020.2020 · DOI · Paper page
  98. Memish, 2016, Viral shedding and antibody response in MERS, Vox Sang, 111, 48
  99. Wang, 2020, Detection of SARS-CoV-2 in different types of clinical specimens, JAMA, 323, 1843
  100. Ip, 2017, Viral shedding and transmission potential of asymptomatic and paucisymptomatic influenza virus infections in the community, Clin Infect Dis, 64, 736, 10.1093/cid/ciw841 · DOI
  101. Walsh, 2020, SARS-CoV-2 detection, viral load and infectivity over the course of an infection, J Infect, 81, 357, 10.1016/j.jinf.2020.06.067 · DOI · Paper page

Cited by

See all 1,350

Metadata

Authors
Cevik, M., Tate, M., Lloyd, O., Maraolo, A. E., Schafers, J., & Ho, A.
Venue
The Lancet Microbe
Publisher
Elsevier BV
Published
2021-01
Volume
2
Issue
1
Pages
e13-e22
ISSN
2666-5247 (ISSN-L)
DOI
10.1016/s2666-5247(20)30172-5
OpenAlex
W3104457017
Cited by
1,350
References
7
FWCI
15.89
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1016/s2666-5247(20)30172-5
The paper
Cevik, M., Tate, M., Lloyd, O., Maraolo, A. E., Schafers, J., & Ho, A. (2021). SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. The Lancet Microbe. https://doi.org/10.1016/s2666-5247(20)30172-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.